
1. jama. 1984 apr 27;251(16):2103-7.

treatment recurrent genital herpes simplex infections oral acyclovir. a
controlled trial.

reichman rc, badger gj, mertz gj, corey l, richman dd, connor jd, redfield d,
savoia mc, oxman mn, bryson y, et al.

two hundred fifty patients entered multicenter trial evaluate 
efficacy toxicity orally administered acyclovir treatment recurrent
genital herpes. study consisted part a, patients entered the
study within 48 hours onset lesions, part b, patients
self-initiated therapy soon possible onset recurrent
episode. parts, patients received either acyclovir (200 mg) placebo,
five times daily five days. parts, duration virus shedding and
the time crusting healing lesions shorter among acyclovir
recipients among placebo recipients. part b, fewer acyclovir recipients
formed new lesions study medication period placebo
recipients. parts b compared directly, duration virus
shedding times required crusting healing lesions were
significantly shorter among acyclovir recipients part b among acyclovir
recipients part a. significant differences duration itching and
pain times subsequent recurrence noted acyclovir and
placebo groups either part part b. significant toxic adverse
reactions seen acyclovir recipients. oral acyclovir shortens duration
of virus shedding duration lesions patients recurrent genital 
herpes. effects pronounced therapy self-initiated by
patients early course recurrent episode.


pmid: 6368877  [indexed medline]

